Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
about
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.Associations between CTLA-4 +49 A/G (rs231775) polymorphism and cancer risk: a meta-analysis based on 52 case-control studiesBlockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferonHarnessing the immune system for the treatment of melanoma: current status and future prospects.Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".Lack of association between cytotoxic T-lymphocyte antigen-4 -318C/T polymorphism and cancer risk: a meta-analysis of case-control studies.Evaluation of polymorphism, hypermethylation and expression pattern of CTLA4 gene in a sample of Iranian patients with schizophrenia.CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemiaMelanoma & biomarkers of immunoresponsiveness
P2860
Q34387506-F694AA4D-7E95-4BF9-91B4-48DC20F19FB2Q34651347-AC8B3D2A-C14B-4AA0-977A-0080FFCA5395Q35870600-3AA27471-B26C-44A5-B645-B8A157F7D616Q37014061-C2FE49D3-312C-4938-9382-7A33CE79006FQ37520710-471FD3F5-1C76-4A4F-B4B6-262FC808D2D8Q38806243-923E8CB7-7927-4076-BB71-15E7DD6139E7Q40226135-3C165C1F-C136-4F19-AF2E-B1216F32E8B7Q43127268-3A1F4C11-39B7-4C62-A31D-0557CD96A80FQ50928165-DB60A9D6-3515-4F05-BF4B-BC10613739CBQ51000594-E453C173-F1D4-44C9-8FF8-A7D17EE7EBF2Q56898205-E8963FB2-F8F9-4C28-AACE-DDA721A83463Q58234468-B4214332-B4BC-4492-8F31-F89D8BE5C854
P2860
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@ast
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@en
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@nl
type
label
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@ast
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@en
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@nl
prefLabel
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@ast
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@en
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@nl
P2093
P2860
P356
P1476
Evaluation of six CTLA-4 polym ...... the He13A/98 multicenter trial
@en
P2093
Alexandros Stratigos
Aristidis Polyzos
Dimosthenis Tsoutsos
Eirini Pectasides
Elizabeth Buchbinder
George Fountzilas
Helen Gogas
Henry Koon
John M Kirkwood
Maria Spyropoulou-Vlachou
P2860
P2888
P356
10.1186/1479-5876-8-108
P577
2010-11-03T00:00:00Z